Search ELTP
ELITE PHARMACEUTICALS INC /NV/
OTC · CIK 1053369
Last close0.23
Daily change+0.00 (0.00%)
10 Years gain+35.29%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
ELTP · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 0331
Fundamental
84.9Momentum
100.0Acceleration
100.0Confidence
91.0Annual Revenue16
Quarterly Revenue61
Annual CFO14
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality17.1 / 25
Capital Efficiency20.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics3.6 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 4.0954 percentage points.
Operating leverageOperating margin improved by 15.3452 percentage points.
ROIC expansionROIC improved by 47.8424 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Key Metrics
Revenue Growth TTM107.85%OK
Revenue CAGR 3Y63.35%OK
Gross Margin48.24%OK
Operating Margin33.07%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC73.84%OK
Incremental Operating Margin 3Y38.09%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y5.65%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026 FY Mar 31, 2026 | $148.87M | $75.02M | $49.11M | $23.75M | $22.82M | 50.4% | 32.99% | 15.33% | 70.3% | 1.14B |
| 2026 FY Mar 31, 2025 | $84.04M | $40.09M | $19.60M | $7.46M | $5.83M | 47.7% | 23.32% | 6.94% | 33.58% | 1.07B |
| 2025 FY Mar 31, 2024 | $56.63M | $26.36M | $10.79M | -$3.24M | -$4.04M | 46.55% | 19.05% | -7.14% | 19.59% | 1.02B |
| 2024 FY Mar 31, 2023 | $34.16M | $16.59M | $3.68M | $3.34M | -$2.40M | 48.58% | 10.76% | -7.02% | 16.77% | 1.01B |
| 2023 FY Mar 31, 2022 | $32.26M | $14.80M | $5.07M | $6.51M | $6.01M | 45.86% | 15.72% | 18.63% | 22.63% | 1.01B |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $140.48M | sum latest 4 fiscal quarters Revenue | OK | 0001493152-26-037752, 0001493152-25-023477 |
| Revenue Growth TTM | 107.85% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001493152-26-037752, 0001493152-25-023477 |
| Revenue CAGR 3Y | 63.35% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001493152-26-031070 |
| Revenue CAGR 5Y | 42.45% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001493152-26-031070 |
| Gross Profit CAGR 3Y | 65.35% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001493152-26-031070 |
| Operating Income Growth | 287.79% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001493152-26-037752, 0001493152-25-023477 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 48.24% | Gross Profit / Revenue | OK | 0001493152-26-037752, 0001493152-25-023477 |
| Operating Margin | 33.07% | Operating Income / Revenue | OK | 0001493152-26-037752, 0001493152-25-023477 |
| ROIC | 73.84% | NOPAT / Average Invested Capital | OK | 0001493152-26-037752, 0001493152-25-023477 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001493152-26-037752 |
| Current Ratio | 3.76x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.12 | Revenue / Diluted Shares | OK | 0001493152-26-037752, 0001493152-25-023477 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |